Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Unifying the classification of acute myeloid leukemia, myelodysplasia-related: A multi-institutional experience

Ying Liu, Derek Loneman, Brenden Bready, David Nemirovsky, Xin Wang, Eytan Stein, Andriy Derkach, Robert Hasserjian, Wenbin Xiao

Blood (2025) 146 (Supplement 1): 219.

https://doi.org/10.1182/blood-2025-219

Published: 2025

Journal Articles

Functionally high-risk disease is associated with inferior outcomes after chimeric antigen receptor T-cell therapy for relapsed refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 2291.

https://doi.org/10.1182/blood-2025-2291

Published: 2025

Journal Articles

Fludarabine pharmacokinetic model identifies an optimal exposure associated with improved outcomes in allogeneic hematopoietic cell transplantation recipients receiving post-transplant cyclophosphamide

Blood (2025) 146 (Supplement 1): 113.

https://doi.org/10.1182/blood-2025-113

Published: 2025

Journal Articles

Updated results from a Phase II study of minimal residual disease-guided venetoclax + obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 3902.

https://doi.org/10.1182/blood-2025-3902

Published: 2025

Journal Articles

A Phase II multicenter study of minimal residual disease-guided, time-limited acalabrutinib + obinutuzumab for the initial treatment of chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 5676.

https://doi.org/10.1182/blood-2025-5676

Published: 2025

Journal Articles

A target trial emulation to assess the comparative incidences of venous thromboembolism in patients with chemotherapy induced thrombocytopenia treated with romiplostim.

Divyash Shah, Cy R. Wilkins, Andriy Derkach, David Nemirovsky, Simon Mantha, Galia Spectre, Jeffrey Zwicker, Avi Leader

Blood (2025) 146 (Supplement 1): 21.

https://doi.org/10.1182/blood-2025-21

Published: 2025

Journal Articles

Real-world administration blinatumomab in the outpatient setting: Toxicity outcomes and healthcare utilization

Yannis Valtis, Benjamin Frost, David Nemirovsky, Andriy Derkach, Kuo-Kai Chin, Meira Yisraeli Salman, Leora Boussi, Natalia Tijaro Ovalle, Eytan Stein, Emilie Baxter, Mark Geyer, Marlise Luskin, Daniel Deangelo, Jae Park, Evan Chen

Blood (2025) 146 (Supplement 1): 1078.

https://doi.org/10.1182/blood-2025-1078

Published: 2025

Journal Articles

Prognosis in adults with ph-positive B-ALL in first complete remission without minimal residual disease after blinatumomab consolidation is influenced by minimal residual disease (≥10-4) pre-blinatumomab

Blood (2025) 146 (Supplement 1): 3329.

https://doi.org/10.1182/blood-2025-3329

Published: 2025

Journal Articles

Immune-MRD Status Informs Tumor-MRD Outcome Prognostication in Multiple Myeloma Patients on Lenalidomide Maintenance

Blood (2024) 144 (Supplement 1): 672.

https://doi.org/10.1182/blood-2024-206646

Published: 2024

Journal Articles

NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival

Yannis K. Valtis, David Nemirovsky, Sean M. Devlin, Gregory W Roloff, Ibrahim Aldoss, Nikeshan Jeyakumar, Katharine Miller, Amy Zhang, Katherine C. Sutherland, Anjali S. Advani, Marlise R. Luskin, Evan C. Chen, Omer Jamy, Michael R. Grunwald, Ibrahim Muhsen, Noam E. Kopmar, Bhagirathbhai Dholaria, Simone E. Dekker, Jessica T. Leonard, George Yaghmour, Stephanie B. Tsai, Wendy Stock, Jozal Moore, Kristen M. O'Dwyer, Aaron C. Logan, Matthew P Connor, Noelle Frey, Evandro Bezerra, Sumithira Vasu, Kaitlyn C Dykes, Minoo Battiwalla, Chenyu Lin, Matthew Ulrickson, Ran Reshef, Ryan D. Cassaday, Laquisha C. Hill, Catherine J. Lee, Vamsi K. Kota, Jacob Boccucci, Joshua Sasine, Akil Merchant, Vinod Pullarkat, Amelia Langston, Talal Hilal, Rawan Faramand, Melhem M. Solh, Tamer Othman, Timothy E O'Connor, Navneet Majhail, Shabaz Malik, Luke Mountjoy, Rasmus T. Hoeg, Caspian H. Oliai, Vishal Gupta, Divya Koura, Muthu V. Kumaran, Marc Schwartz, Veronika Bachanova, Sean I. Tracy, Maria Odstrcil Bobillo, Abdullah Ladha, Clayton Jackson, Vivian Irrizary Gatell, Olalekan O. Oluwole, Michael Daunov, John Mathews, Paul Shaughnessy, Bijal D Shah, Lori Muffly, Jae H. Park

Blood (2024) 144 (Supplement 1): 4200.

https://doi.org/10.1182/blood-2024-201610

Published: 2024

Journal Articles

Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Blood (2024) 144 (Supplement 1): 5166.

https://doi.org/10.1182/blood-2024-210518

Published: 2024

Journal Articles

Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2024) 144 (Supplement 1): 1010.

https://doi.org/10.1182/blood-2024-203807

Published: 2024

Journal Articles

Outpatient Vs Inpatient Hidac Consolidation for AML: The MSKCC Experience

Leora Boussi, Hannah Burton, Andriy Derkach, David Nemirovsky, Jenna Ciervo, Martin S. Tallman, Eytan M. Stein, Sheng Cai

Blood (2024) 144 (Supplement 1): 445.

https://doi.org/10.1182/blood-2024-204449

Published: 2024

Journal Articles

Imaging Predictors of Intracerebral Hemorrhage in Patients with Brain Tumors Treated with Anticoagulation

Blood (2024) 144 (Supplement 1): 1246.

https://doi.org/10.1182/blood-2024-199172

Published: 2024

Journal Articles

Comparison of Acute Kidney Injury in Patients with Relapsed or Refractory Multiple Myeloma Following CAR T-Cell and Bispecific Antibody Therapies

Blood (2024) 144 (Supplement 1): 6944.

https://doi.org/10.1182/blood-2024-212006

Published: 2024

Journal Articles

Infectious Complications during Treatment with Commercial CAR T-Cell Therapy and Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 6935.

https://doi.org/10.1182/blood-2024-207977

Published: 2024

Journal Articles

Patients with AML and an IDH2-R172 Mutation Exhibit a Unique Response to Intensive Induction Chemotherapy, Suggesting Futility of Mid-Cycle Bone Marrow Biopsy and Caution When Considering Re-Induction

Meira Yisraeli Salman, Alexander R. Terry, Andriy Derkach, David Nemirovsky, Kuo-Kai Chin, Yannis K. Valtis, Leora Boussi, Theresa Spivey, Wenbin Xiao, Christopher Famulare, Jenna Ciervo, Jacob M. Rowe, Martin S. Tallman, Eytan M. Stein

Blood (2024) 144 (Supplement 1): 2847.

https://doi.org/10.1182/blood-2024-193242

Published: 2024

Journal Articles

Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy

Blood (2024) 144 (Supplement 1): 1250.

https://doi.org/10.1182/blood-2024-201997

Published: 2024

Journal Articles

Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients

Blood (2023) 142 (Supplement 1): 3370.

https://doi.org/10.1182/blood-2023-187891

Published: 2023

Journal Articles

Evaluating the Effect of Evolving Changes in Serum Biomarkers on the Risk of Progression in Smoldering Multiple Myeloma

Blood (2023) 142 (Supplement 1): 877.

https://doi.org/10.1182/blood-2023-180315

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Unifying the classification of acute myeloid leukemia, myelodysplasia-related: A multi-institutional experience

Functionally high-risk disease is associated with inferior outcomes after chimeric antigen receptor T-cell therapy for relapsed refractory multiple myeloma

Fludarabine pharmacokinetic model identifies an optimal exposure associated with improved outcomes in allogeneic hematopoietic cell transplantation recipients receiving post-transplant cyclophosphamide

Updated results from a Phase II study of minimal residual disease-guided venetoclax + obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia

A Phase II multicenter study of minimal residual disease-guided, time-limited acalabrutinib + obinutuzumab for the initial treatment of chronic lymphocytic leukemia

A target trial emulation to assess the comparative incidences of venous thromboembolism in patients with chemotherapy induced thrombocytopenia treated with romiplostim.

Real-world administration blinatumomab in the outpatient setting: Toxicity outcomes and healthcare utilization

Prognosis in adults with ph-positive B-ALL in first complete remission without minimal residual disease after blinatumomab consolidation is influenced by minimal residual disease (≥10-4) pre-blinatumomab

Immune-MRD Status Informs Tumor-MRD Outcome Prognostication in Multiple Myeloma Patients on Lenalidomide Maintenance

NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival

Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)

Outpatient Vs Inpatient Hidac Consolidation for AML: The MSKCC Experience

Imaging Predictors of Intracerebral Hemorrhage in Patients with Brain Tumors Treated with Anticoagulation

Comparison of Acute Kidney Injury in Patients with Relapsed or Refractory Multiple Myeloma Following CAR T-Cell and Bispecific Antibody Therapies

Infectious Complications during Treatment with Commercial CAR T-Cell Therapy and Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma

Patients with AML and an IDH2-R172 Mutation Exhibit a Unique Response to Intensive Induction Chemotherapy, Suggesting Futility of Mid-Cycle Bone Marrow Biopsy and Caution When Considering Re-Induction

Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy

Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients

Evaluating the Effect of Evolving Changes in Serum Biomarkers on the Risk of Progression in Smoldering Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only